Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.41 |
| ▸ | PPARD | Q03181 | 6/20 | 0.39 |
| ▸ | THRA | P10827 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 8/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961775 | 0.90 | FFAR4 (0.41) | FFAR4PPARDPPARAFFAR1PPARG | |
| SCHEMBL3962231 | 0.89 | FFAR4 (0.43) | FFAR4PPARDPPARAFABP4PPARG | |
| SCHEMBL3962612 | 0.88 | CYP11B1 (0.42) | FFAR4THRATHRBFABP4 | |
| SCHEMBL3966733 | 0.80 | PPARD (0.48) | FFAR4PPARDPPARAFFAR1PPARG | |
| SCHEMBL4192187 | 0.80 | CYP11B1 (0.43) | FFAR4FABP4 | |
| SCHEMBL3965826 | 0.78 | PPARD (0.43) | FFAR4PPARDPPARAFFAR1PPARG | |
| SCHEMBL3970524 | 0.78 | PPARD (0.43) | FFAR4PPARDPPARAFFAR1PPARG | |
| SCHEMBL3965823 | 0.78 | PPARD (0.43) | FFAR4PPARDPPARAFFAR1PPARG | |
| SCHEMBL3970781 | 0.78 | CYP11B1 (0.44) | FFAR4FABP4 | |
| SCHEMBL3961619 | 0.77 | PPARD (0.42) | FFAR4PPARDPPARAFFAR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | FFAR4 237/4885PPARD 88/4885THRA 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.